Search Results - Niklas Gremke
- Showing 1 - 4 results of 4
-
1
-
2
mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability by Niklas Gremke, Pierfrancesco Polo, Aaron Dort, Jean Schneikert, Sabrina Elmshäuser, Corinna U. Brehm, Ursula Klingmüller, Anna Schmitt, Hans Christian Reinhardt, Oleg Timofeev, Michael Wanzel, Thorsten Stiewe
Published 2020Artigo -
3
CRISPR-Cas9–based target validation for p53-reactivating model compounds by Michael Wanzel, Jonas B. Vischedyk, Miriam P. Gittler, Niklas Gremke, Julia R. Seiz, Mirjam Hefter, Magdalena Noack, Rajkumar Savai, Marco Mernberger, Joël P. Charles, Jean Schneikert, Anne Catherine Bretz, Andrea Nist, Thorsten Stiewe
Published 2015Artigo -
4
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs by Niklas Gremke, Isabelle Besong, A. Stroh, Luise von Wichert, Marie Witt, Sabrina Elmshäuser, Michael Wanzel, Martin F. Fromm, R. Verena Taudte, Sabine Schmatloch, Thomas Karn, Mattea Reinisch, Nader Hirmas, S. Loibl, Thomas Wündisch, Anne‐Sophie Litmeyer, Paul Jank, Carsten Denkert, Sebastian Griewing, Uwe Wagner, Thorsten Stiewe
Published 2025Artigo
Search Tools:
Related Subjects
Cancer
Biology
Cancer research
Genetics
Apoptosis
Autophagy
Breast cancer
Cell biology
Computational biology
Gene
Medicine
PI3K/AKT/mTOR pathway
Pharmacology
Signal transduction
Biochemistry
Bioinformatics
CRISPR
Cancer drugs
Cas9
Computer science
Computer security
Concordance
DNA
DNA damage
Discovery and development of mTOR inhibitors
Drug
Drug discovery
Drug resistance
Druggability
Family medicine